{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:40:29Z","timestamp":1779237629767,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T00:00:00Z","timestamp":1595116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Brentuximab vedotin is a monoclonal antibody drug conjugate used for the treatment of patients with Hodgkin lymphoma. Hypersensitivity reactions to brentuximab vedotin may include cutaneous, cardiovascular, respiratory, gastrointestinal and neurological signs and symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We present the case of a 23-year-old Mexican female with stage IV progressive classical nodular sclerosing Hodgkin lymphoma who received multiple previous chemotherapy regimens. Brentuximab vedotin at 1.8\u2009mg\/kg (180\u2009mg total dose), for 21-day cycles was indicated. Within 5\u2009min of infusion of the 5th cycle of brentuximab, she developed severe anaphylaxis (hives, angioedema, diaphoresis, tachycardia, dyspnea, hypoxemia and loss of consciousness), which was successfully controlled with epinephrine, steroids and antihistamines.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Management and outcome:<\/jats:bold>\n                      Intradermal skin test at a concentration of 0.1\u2009mg\/ml was positive. Due to the severity of the symptoms and the lack of access to alternative treatments, we performed a desensitization protocol. A total of 180\u2009mg of brentuximab was given in three\u2009bag solutions in 12 steps, with an initial concentration dose of 1\/100 of the total dose in a course of 5.56\u2009h with no hypersensitivity reactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Severe anaphylaxis has been reported in 1.2% of patients receiving brentuximab vedotin. Patients who are treated by rapid drug desensitization with their first option therapy present a favorable survival rate with better cost-effectiveness in comparison to second-line treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220942292","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T02:49:42Z","timestamp":1595213382000},"page":"505-508","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin\u2019s lymphoma"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6023-6934","authenticated-orcid":false,"given":"Rosalaura","family":"V. Villarreal-Gonzalez","sequence":"first","affiliation":[{"name":"Regional Center of Allergy and Clinical Immunology, University Hospital \u201cDr. Jose Eleuterio Gonzalez\u201d, Faculty of Medicine, Autonomous University of Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"N. Gonzalez-Diaz","sequence":"additional","affiliation":[{"name":"Regional Center of Allergy and Clinical Immunology, University Hospital \u201cDr. Jose Eleuterio Gonzalez\u201d, Faculty of Medicine, Autonomous University of Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-8130","authenticated-orcid":false,"given":"Cindy","family":"E. de Lira-Quezada","sequence":"additional","affiliation":[{"name":"Regional Center of Allergy and Clinical Immunology, University Hospital \u201cDr. Jose Eleuterio Gonzalez\u201d, Faculty of Medicine, Autonomous University of Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"G\u00f3mez-Almaguer","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital \u201cDr. Jose Eleuterio Gonzalez\u201d, Faculty of Medicine, Autonomous University of Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"G\u00f3mez-De Le\u00f3n","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital \u201cDr. Jose Eleuterio Gonzalez\u201d, Faculty of Medicine, Autonomous University of Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalhie","family":"Acu\u00f1a-Ortega","sequence":"additional","affiliation":[{"name":"Regional Center of Allergy and Clinical Immunology, University Hospital \u201cDr. Jose Eleuterio Gonzalez\u201d, Faculty of Medicine, Autonomous University of Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,7,19]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.07.003"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.01.012"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.018"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.04.015"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.12.006"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000550"},{"key":"e_1_3_6_9_2","first-page":"e2981","article-title":"Desensitization of brentuximab vedotin in a patient with Hodgkin lymphoma.","volume":"10","author":"Khalid S","unstructured":"Khalid S, Khalid A, Clark B A, et\u00a0al. Desensitization of brentuximab vedotin in a patient with Hodgkin lymphoma. Cureus 2018; 10: e2981.","journal-title":"Cureus 2018;"},{"key":"e_1_3_6_10_2","first-page":"626","article-title":"Brentuximab vedotin infusion reaction management: a case study","volume":"8","author":"Comer MSN","year":"2017","unstructured":"Comer MSN, APRN H, Cardwell MSN, APRN K. Brentuximab vedotin infusion reaction management: a case study. J Adv Pract Oncol 2017; 8: 626\u2013629.","journal-title":"J Adv Pract Oncol"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220942292","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220942292","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220942292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:23Z","timestamp":1777688603000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220942292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,19]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1177\/1078155220942292"],"URL":"https:\/\/doi.org\/10.1177\/1078155220942292","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,19]]}}}